Foundational research · 2022: SURMOUNT-1 weight change at 72 weeks
Source publication date
Site published
Among adults without diabetes, tirzepatide 5/10/15 mg yielded mean weight changes of -15.0/-19.5/-20.9%, versus -3.1% with placebo over 72 weeks. Eligibility: BMI at least 30, or at least 27 with a weight-related complication. DOI: 10.1056/NEJMoa2206038.
Summary
Historical evidence from a phase 3 randomized trial involving 2,539 adults.
Editorial view
Editorial view: distinguish body-weight outcomes from local body contouring.
Evidence and limitations
Lilly-funded; gastrointestinal adverse events occurred. Not evidence of longevity or device efficacy.